Press coverage about Scpharmaceuticals (NASDAQ:SCPH) has trended somewhat negative on Friday, according to Accern. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Scpharmaceuticals earned a media sentiment score of -0.10 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.7804265488388 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have effected Accern’s analysis:
- Scpharmaceuticals (SCPH) Upgraded at Zacks Investment Research (americanbankingnews.com)
- Leerink Swann Weighs in on Scpharmaceuticals Inc’s Q1 2018 Earnings (SCPH) (americanbankingnews.com)
- FY2022 Earnings Estimate for Scpharmaceuticals Inc (SCPH) Issued By Leerink Swann (americanbankingnews.com)
- Scpharmaceuticals Inc (SCPH) to Post FY2019 Earnings of ($2.36) Per Share, Jefferies Group Forecasts (americanbankingnews.com)
NASDAQ:SCPH opened at $12.40 on Friday. Scpharmaceuticals has a twelve month low of $11.11 and a twelve month high of $18.17. The company has a current ratio of 24.12, a quick ratio of 24.12 and a debt-to-equity ratio of 0.09.
SCPH has been the topic of a number of recent analyst reports. Leerink Swann assumed coverage on shares of Scpharmaceuticals in a report on Tuesday, December 12th. They set an “outperform” rating and a $20.00 target price on the stock. BMO Capital Markets initiated coverage on shares of Scpharmaceuticals in a research report on Tuesday, December 12th. They set an “outperform” rating and a $24.00 price objective for the company. Jefferies Group initiated coverage on shares of Scpharmaceuticals in a research report on Tuesday, December 12th. They set a “buy” rating and a $23.00 price objective for the company. Finally, Zacks Investment Research cut shares of Scpharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 14th.
WARNING: This report was reported by BBNS and is the property of of BBNS. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://baseballnewssource.com/2018/03/30/somewhat-negative-news-coverage-somewhat-unlikely-to-impact-scpharmaceuticals-scph-share-price/1973616.html.
Scpharmaceuticals Company Profile
scPharmaceuticals, Inc, is a biopharmaceutical company. The Company is engaged in developing pharmaceutical products for subcutaneous delivery. The Company offers sc2Wear Infusor, which is a small pump that attaches to the body using a standard medical adhesive. The sc2Wear Infusor injects the drug into the body slowly, similar to an intravenous (IV) drip.
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.